NCT02737319

A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).

A Randomized Trial of Rosuvastatin in Elective Percutaneous Coronary Intervention to Prevent Contrast-induced (CLEAR-CIN).

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 493 (actual)
• Sponsor: University of Sao Paulo · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The investigators analyzed the HMG-CoA reductase inhibitor, rosuvastatin, for the prevention of contrast-medium-induced nephropathy in patients undergoing primary angioplasty.

Detailed description

Patients with stable coronary artery disease already taking chronic statin undergoing elective angioplasty are at risk for contrast-medium-induced nephropathy because there are specified risk factors as age more than 75 years, chronic renal insufficiency, diabetes, use of contrast and the lack of effective prophylaxis.

Conditions

• Nephropathy

Interventions

Type	Name	Description
DRUG	Rosuvastatin	40 mg of rosuvastatin before angioplasty

Timeline

• Start date: 2011-03-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2016-04-13
• Last updated: 2016-04-14

Locations

1 site across 1 country: Brazil